Patients were randomized to receive either PegIntron (1.5 µg/kg/week) plus ribavirin (800 mg/day) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
RÜ TIW) pluss ribaviriini (800 mg/ ööpäevas) 48 nädala jooksul, millele järgnes 6- kuuline jälgimisperiood.